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INTRODUCTION 
Bi-layer tablets have been developed to achieve 
controlled delivery of different drugs with pre-defined 
release profiles.  Bi-layer tablets can be a primary option 
to avoid chemical incompatibilities between API by 
physical separation, and to enable the development of 
different drug release profiles (immediate release with 
extended release). Despite their advantages, due to the 
use of different materials and complex geometric 
boundaries between the adjacent layers, the mechanical 
structures of this drug delivery system have become 
quite intricate, requiring complicated tablet architectures 
as well as patient-friendly. 
The most common controlled delivery system has been 
the matrix type such as tablets and granules where the 
drug is uniformly dissolved or dispersed throughout the 
polymer, because of its effectiveness, low cost, ease of 
manufacturing and prolonged delivery time period
1,2
. Bi-
layer tablets have some key advantages compared to 
conventional monolayer tablets. For instance, such 
tablets are commonly used to avoid chemical 
incompatibilities of formulation components by physical 
separation. 
The bi-layer tablet is a concept which is composed of 
different layers. The system allows the incorporation of 
more than one drug into the dosage form 3-4. Formulation 
of layers from different polymers allows manipulation 
over more than one rate-controlling polymer, thus 
enabling different types of drug delivery of one or more 
drugs, i.e. where the drug may be released with a bolus 
and then at a controlled rate or by targeted drug delivery 
in the GI tract using pH dependant polymers5. 
MULTI-LAYER TABLET DOSAGE FORMS ARE 
DESIGNED FOR VARIETY OF REASONS- 
 To control the delivery rate of either single 6 or two 
different active pharmaceutical ingredient(s)7,8. 
 To control the delivery rate of either single or two 
different active pharmaceutical ingredient(s).  
 To separate incompatible Active pharmaceutical 
ingredient (APIs) from each other, to control the 
release of API from one layer by utilizing the 
functional property of the other layer (such as, 
osmotic property).  
 To modify the total surface area available for API 
layer either by sandwiching with one or two inactive 
layers in order to achieve swellable /erodible 
barriers for modified release. 
 To modify the total surface area available for API 
layer either by sandwiching with one or two inactive 
layers in order to achieve swellable /erodible 
barriers for modified release.  
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ABSTRACT  
Bi-layer tablets have been developed to achieve controlled delivery of different drugs with pre-defined release profiles. In the 
last decade, interest in developing a combination of two or more Active Pharmaceutical Ingredients (API) in a single dosage 
form (bilayer tablet) has increased in the pharmaceutical industry, promoting patient convenience and compliance. Bi -layer 
tablet is suitable for sequential release of two drugs in combination, separate two incompatible substances and also for 
sustained release tablet in which one Layer is immediate release as initial dose and second layer is maintenance dose. Bilaye r 
tablets can be a primary option to avoid chemical incompatibilities between API by physical separation, and to enable the 
development of different drug release profiles (immediate release with extended release). There is various application of the 
bilayer tablet it consist of monolithic partially coated or multilayered matrices. 
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ADVANTAGES OF THE BI-LAYER TABLET 
 Bi-Layer execution with optional single-layer 
conversion kit.  
 Cost is lower compared to all other oral dosage 
form.  
 Greatest chemical and microbial stability over all 
oral dosage form.  
 Objectionable odor and bitter taste can be masked by 
coating technique.  
 Flexible Concept. 
DISADVANTAGES OF BI-LAYER TABLET 
DOSAGE FORM ARE  
 Some drugs resist compression into dense compacts, 
owing to amorphous nature, low  density character.  
 Bitter testing drugs, drugs with an objectionable 
odor or drugs that are sensitive to oxygen may 
require encapsulation or coating.  
 Difficult to swallow in case of children and 
unconscious patients.  
 Drugs with poor wetting, slow dissolution 
properties, optimum absorption high in GIT may be 
difficult to formulate or manufacture as a tablet that 
will still provide adequate or full drug 
bioavailability. 
GENERAL PROPERTIES OF BI-LAYER TABLET 
DOSAGE FORMS- 
 A bi-layer tablet should have elegant product 
identity while free of defects like chips, cracks, 
discoloration, and contamination.  
 Should have sufficient strength to withstand 
mechanical shock during its production packaging, 
shipping and dispensing.  
 Should have the chemical and physical stability to 
maintain its physical attributes over time. The bi-
layer tablet must be able to release the medicinal 
agents in a predictable and reproducible manner.  
 Must have a chemical stability shelf-life, so as not to 
follow alteration of the medicinal agents. 
MANUFACTURING PROCESS- 
Manufacturing processes such as wet granulation/roller 
compaction and addition of binders increases the level of 
complexity in understanding the critical factors 
governing compression and tablet breaking force. Thus, 
the tablet breaking force and the tablet’s propensity for 
de-lamination/capping either during manufacturing or 
during storage need to be carefully observed. Apart from 
the critical material attributes of individual components 
and final blend, the tablet press has large influence on the 
manufacture of multilayer tablets. Bilayer tablets are 
composed of two layers of granulation compressed 
together. They have appearance of a sandwich because 
the edges of each layer are exposed. They have the 
appearance of a sandwich because the edges of each 
layer are exposed. Bi-layer tablets are prepared with 
onelayer of drug for immediate release with second layer 
design to release drug, later, either as second dose or in 
an extended release manner
9
. 
 
DRUG RELEASE MECHANISM 
Normally the drug release from hydrophilic swellable 
matrices depends on the polymer macromolecular 
coupling, relaxation and the drug diffusion and all of 
these are responsible on the rate at which water may 
penetrate into the device. Hydration rate, swelling of the 
polymer and modification of the polymer matrix are the 
basics for the multilayered drug delivery design. These 
factors are very effective at the primary or initial phase 
of the drug dissolution but with the respect of time as 
swelling proceeds linearization of the release profile 
occurs. 
To achieve this objective, coating of the matrix tablets 
with an inert impermeable film has been performed. 
Coating plays a very important role in the drug release 
from the multilayered preparations and a number of 
combinations of coating materials are used that is 
schematically represented. The release rate of the drug 
from tablets is observed by in vitro release rate study. 
The release rate of the drug is inversely proportional to 
the extent of coating. The release of the drug is primarily 
dependant on the swelling of the polymer which is again 
controlled by reducing the drug release surface by the 
coating material. When a tablet is coated partially, it does 
not swell and retain its initial size and shape and 
maintain the release retardation continuously through the 
entire dissolution process. On the other hand, when the 
tablet is subjected to water immersion the polymer 
barrier which is inert in nature have a tendency to crack 
and separated out from the core within hours. This effect 
is resulted from volume expansion of core upon water 
immersion due to polymer swelling. The outer barrier 
layer does not expand while the core is swelling as a 
result a stress is generated in the outer barrier layer. 
When the outer barrier is sellable polymer then the both 
barrier and core swell simultaneously without any 
internal stress during the dissolution process. Multilayer 
compression process can be used for the application of 
barriers. One notable example of this phenomena is the 
double layer or three layer tablets in which only one 
layer contains the active ingredient (active core), while 
other layers are barrier layers. The multi-layer design 
allows for the production of different tablet designs by 
varying the geometry of the device or modulating layers 
characterized by specific release properties to achieve 
various dissolution patterns (not limited to a constant 
release) such as delayed, pulsatile or multi modal 
delivery profiles. The section below deals with various 
tablet possibilities based on this proposed design. 
VARIOUS TECHNIQUES FOR BILAYER TABLET 
OROS® PUSH PULL TECHNOLOGY
:
  
This system consist of mainly two or three layers among 
which one or more layers are essential of the drug and 
other layers are consist of push layer. The drug layer 
mainly consists of drug along with two or more different 
agents. So this drug layer comprises of drug which is in 
poorly soluble form. There is further addition of 
suspending agent and osmotic agent. A semi permeable 
membrane surrounds the tablet core10.  
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Figure 1: Oros® Push Pull Technology 
 
BILAYER AND TRILAYER OROS PUSH PULL 
TECHNOLOGY: 
L-OROS tm technology This system used for the 
solubility issue Alza developed the L-OROS system 
where a lipid soft gel product containing drug in a 
dissolved state is initially manufactured and then coated 
with a barrier membrane, then osmotic push layer and 
then a semi permeable membrane, drilled with an exit 
orifice11.                                                                                                                                                                    
 
Figure 2: Bi-layer And Trilayer Oros Push Pull 
Technology 
L – OROS TM TECHNOLOGY :  
This system used for the solubility issue Alza developed 
the L-OROS system where a lipid soft gel product 
containing drug in a dissolved state is initially 
manufactured and then coated with a barrier membrane, 
than osmotic push layer and than a semi permeable 
membrane, drilled with an exit orifice12. 
 
Figure 3: L – Oros Tm Technology 
EN SO TROL TECHNOLOGY 
Solubility enhancement of an order of magnitude or to 
create optimized dosage form Shire laboratory use an 
integrated approach to drug delivery focusing on 
identification and incorporation of the identified 
enhancer into controlled release technologies13.  
 
                  Figure 4: En So Trol Technology 
DUROS TECHNOLOGY: 
DUROS (Alza Corporation) is based on implant 
technology,which provides an alternative for the delivery 
of a wide range of therapeutic compounds, including 
peptides, proteins, and other bioactive macromolecules14. 
 
 
Figure 5: Duros Technology 
VARIOUS ASPECTS OF BILAYER TABLET 
 FLOATING DRUG DELIVERY SYSTEMS 
(FDDS) 
15,16
  
From the formulation and technological point of view, 
the floating drug delivery systems are considerably easy 
and logical approach in the development of Gastro 
retentive dosage forms (GRDFs). 
 APPROACHES TO DESIGN FLOATING 
DRUG DELIVERY SYSTEM 
The following approaches have been used for the design 
of floating dosage forms of singleand multiple-unit 
systems. 
 INTRA GASTRIC BILAYERED FLOATING 
TABLETS 
These are also compressed tablet as shown in 
figure and contain two layers i.e. 
 Immediate release layer and  
 Sustained release layer. 
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Figure 6: Intra Gastric Bilayered Floating Tablets 
 
 MULTIPLE UNIT TYPE FLOATING PILL 
These systems consist of sustained release pills as 
‘seeds’ surrounded by double layers. The inner layer 
consists of effervescent agents while the outer layer is of 
swellable membrane layer. When the system is immersed 
in dissolution medium at body temp, it sinks at once and 
then forms swollen pills like balloons, which float as 
they have lower density. 
 
Figure 7: Multiple Unit Type Floating Pill 
EVALUATION OF BI-LAYER TABLETS 
 Thickness  
 Hardness  
 Size and shape  
 Uniformity of weight 
 Friability  
 Wetting time 
 Water absorption ratio 
 Dissolution study 
Thickness- 
Thickness and diameter of tablets were important for 
uniformity of tablet size. Thickness and diameter was 
measured using venire calliper17. 
Hardness- 
The limit of hardness of MDT is usually kept in lower 
range to facilitate early disintegration in mouth. The 
hardness of MDTS may be measured using hardness 
tester ( Monsanto Hardness tester ). It is expressed in kg 
or pound18. 
Size and shape- 
Size and shape of the tablet can be dimensionally 
described, monitored and controlled.  
Uniformity of weight- 
Weight variation test is done as per standard procedure. 
Ten tablets from each formulation are weighed using an 
electronic balance and the average weigh are calculated. 
Friability- 
Friability is the measure of tablet strength. Twenty 
tablets were weighed accurately and placed in the 
tumbling apparatus that revolves at 25 rpm dropping the 
tablets through a distance of six inches with each 
revolution. After 4 min, the tablets were weighed and the 
percentage loss in tablet weight was determined. % loss 
= [(Initial wt. of tablets – Final wt. of tablets)/ Initial wt. 
of tablets] ×10019. 
Wetting time- 
Five circular tissue papers of 10 cm diameter are placed 
in a petridish with a 10 cm diameter. Ten millimeters of 
water-containing Eosin, a water-soluble dye, is added to 
petridish. A tablet is carefully placed on the surface of 
the tissue paper. The time required for water to reach 
upper surface of the tablet is noted as a wetting time20. 
Water Absorption Ratio- 
A piece of tissue paper folded twice was placed in a 
small Petri dish containing 6 ml of water. A tablet was 
put on the paper & the time required for complete 
wetting was measured. The wetted tablet was then 
weighed. Water absorption ratio (R), was determined 
using following equation,  
R = 10 ( Wa /Wb)  
Where- Wb is weight of tablet before water absorption & 
Wa is weight of tablet after water absorption21. 
DISSOLUTION STUDY- 
Bilayer tablets were subjected to in vitro drug release 
studies in simulated gastric and intestinal fluids to assess 
their ability in providing the desired controlled drug 
delivery. Drug release studies were carried out using 
USP dissolution test apparatus I at 100 rpm, 37±0.5°C, 
and pH 1.2 buffer (900 ml) (i.e. 0.1 N HCl) for 2 hours, 
since the average gastric emptying time is about 2 hours. 
The dissolution medium was replaced with pH 6.8 
phosphate buffer (900 ml) and experiment continued for 
another 10 hours. At different time intervals, 5ml of the 
samples were withdrawn and replaced with 5ml of drug-
free dissolution medium. The samples withdrawn were 
analyzed by UV spectrophotometer using multi 
component mode of analysis22. 
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COMMERCIALLY MARKETED BI-LAYER TABLETS 
Product Name Chemical Name Developer 
Glycomet®-GP2Forte Metformin hydrochloride, Glimepiride USV Limited 
ALPRAX PLUS Sertraline, Alprazolam Torrent Pharmaceutcals Ltd. 
DIAMICRON®XRMEX500 Gliclazide, Metformin hydrochloride Sedia® Pharmaceuticals (India) Pvt. Ltd. 
Newcold Plus 
Levocetrizine             hydrochloride,          
Phenylpropanolamine, Paracetamol 
Piramol Healthcare Ltd. 
TRIOMUNE 30 Nevirapine, Lamivudine, Stavudine Cipla Ltd. 
DIUCONTIN-K®20/250 Furosemide, Potassium chloride T.C. Health Care Pvt. Ltd. 
Tribet-1 
Glimepiride,            Pioglitazone               
hydrochloride,          Metformin  HCl 
Abbott Healthcare Pvt. Ltd. 
PIOKIND®-M15 Pioglitazone, Metformin  HCl Psychotropics India Ltd. 
Revelol®-Am 25/5 Metoprolol succinate, Amlodipine besilate Ipca Laboratories Ltd. 
 
CONCLUSION 
Bi-layer tablet is improved beneficial technology to 
overcome the shortcoming of the single tablet. Bi-layer 
tablet is suitable for sequential release of two drugs in 
combination, separate two incompatible substances and 
also for sustained release tablet in which one layer is 
immediate release as initial dose and second is 
maintenance dose. The preparation of tablets in the form 
of multi layers is used to provide systems for the 
administration of drugs, which are incompatible and to 
provide controlled release tablet preparations by 
providing surrounding or multiple swelling layers. 
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